血清高同型半胱氨酸在多发性骨髓瘤治疗及预后中的临床效果评价(1)
[摘要] 目的 探究血清高同型半胱氨酸(Hcy)在多發性骨髓瘤患者接受治疗以及预后中的临床评价效果，分析其临床应用意义。方法 整群选取该院2016年1月—2018年12月间收入的所有多发性骨髓瘤患者60例开展研究，设为实验组，应用PDD方案进行治疗，治疗前后进行血清高同型半胱氨酸(Hcy)检验。同时收录该院同期60名健康体检人员的一般资料及血清高同型半胱氨酸(Hcy)检查结果，作为对照组。实验组患者在4～6个疗程结束后，评价治疗前后，治疗有效及无效者之间血清高同型半胱氨酸(Hcy)数值的变化，分析其相关性。结果 实验结果显示，经治疗后，实验组患者的各项血清指标均有所改善，且与对照组相比差异无统计学意义(P>0.05)。 其血清高同型半胱氨酸数据为(18.65±3.67)μmol/L，对照组数据为(17.25±2.97)μmol/L。实验组与对照组相比，差异无统计学意义(t=1.068，P>0.05)。实验组患者在治疗完成后，其客观总缓解率为85.00%。结论 血清高同型半胱氨酸在多发性骨髓瘤患者中数据会出现明显增长状况，而采用PDD方案对患者进行治疗，能够有效提高患者的病情缓解率，同时也能降低患者体内的血清高同型半胱氨酸数值。除此之外，血清高同型半胱氨酸的高低对治疗效果的判定以及预后估计有一定参考意义。
[关键词] 血清高同型半胱氨酸;PDD方案;多发性骨髓瘤;治疗效果
[中图分类号] R733.3 [文献标识码] A [文章编号] 1674-0742(2019)10(c)-0121-03
[Abstract] Objective To investigate the clinical evaluation effect of serum homocysteine (Hcy) in the treatment and prognosis of patients with multiple myeloma， and to analyze its clinical application significance. Methods Convenient selected a total of 60 patients with multiple myeloma who were enrolled in the hospital from January 2016 to December 2018 were enrolled in the study. The experimental group was treated with PDD. The serum homocysteine was administered before and after treatment (Hcy) test. At the same time， the general information of 60 healthy medical examiners in the same period of our hospital and the results of serum homocysteine(Hcy) were collected as the control group. In the experimental group， after the end of 4-6 courses， the changes of serum high homocysteine(Hcy) values between the effective and ineffective patients were evaluated before and after treatment， and the correlation was analyzed. Results The experimental results showed that after treatment， the serum indexes of the experimental group were improved， and there was no statistically significant difference compared with the control group (P>0.05). The serum homocysteine data of the experiment al group was (18.65±3.67) μmol/L， and the control data was (17.25±2.97) μmol/L. There was no statistically significant difference between the experimental group and the control group (t=1.068， P>0.05). The objective total response rate of the experimental group patients after the completion of treatment was 85.00%. Conclusion Serum high homocysteine has a significant increase in the number of patients with multiple myeloma， and the treatment with PDD can effectively improve the patient's disease remission rate and also reduce the serum homoisotype cysteine value in patients. In addition， the level of serum homocysteine has a certain reference value for the determination of treatment effect and prognosis estimation., 百拇医药(王瑾碧 王缨 倪静)
[关键词] 血清高同型半胱氨酸;PDD方案;多发性骨髓瘤;治疗效果
[中图分类号] R733.3 [文献标识码] A [文章编号] 1674-0742(2019)10(c)-0121-03
[Abstract] Objective To investigate the clinical evaluation effect of serum homocysteine (Hcy) in the treatment and prognosis of patients with multiple myeloma， and to analyze its clinical application significance. Methods Convenient selected a total of 60 patients with multiple myeloma who were enrolled in the hospital from January 2016 to December 2018 were enrolled in the study. The experimental group was treated with PDD. The serum homocysteine was administered before and after treatment (Hcy) test. At the same time， the general information of 60 healthy medical examiners in the same period of our hospital and the results of serum homocysteine(Hcy) were collected as the control group. In the experimental group， after the end of 4-6 courses， the changes of serum high homocysteine(Hcy) values between the effective and ineffective patients were evaluated before and after treatment， and the correlation was analyzed. Results The experimental results showed that after treatment， the serum indexes of the experimental group were improved， and there was no statistically significant difference compared with the control group (P>0.05). The serum homocysteine data of the experiment al group was (18.65±3.67) μmol/L， and the control data was (17.25±2.97) μmol/L. There was no statistically significant difference between the experimental group and the control group (t=1.068， P>0.05). The objective total response rate of the experimental group patients after the completion of treatment was 85.00%. Conclusion Serum high homocysteine has a significant increase in the number of patients with multiple myeloma， and the treatment with PDD can effectively improve the patient's disease remission rate and also reduce the serum homoisotype cysteine value in patients. In addition， the level of serum homocysteine has a certain reference value for the determination of treatment effect and prognosis estimation., 百拇医药(王瑾碧 王缨 倪静)